GlassScriptPhysician profile
Maribel Aguilera
NPI 1659343283
$117,910.32
in general payments reported to CMS, 2019-2025
26 companies · $11K in 2025
The $11K reported for 2025 was more than what 96% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,716 · 2020: $7,798 · 2021: $13K · 2022: $39K · 2023: $25K · 2024: $21K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $46K · Food and Beverage: $7,671 · Consulting Fee: $2,000 · Travel and Lodging: $755 · Education: $76.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $46,125.00 |
| Food and Beverage | $7,671.30 |
| Consulting Fee | $2,000.00 |
| Travel and Lodging | $754.50 |
| Education | $76.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $95,674.77 | 2021-2025 | Vraylar |
| Allergan, INC. | $7,085.71 | 2019-2020 | |
| Axsome Therapeutics, INC. | $3,042.09 | 2022-2025 | Auvelity |
| Lundbeck LLC | $2,612.68 | 2019-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,808.88 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $1,176.86 | 2019-2025 | Spravato |
| Otsuka America Pharmaceutical, INC. | $1,032.63 | 2019-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Sunovion Pharmaceuticals INC. | $901.53 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $677.45 | 2019-2024 | Uzedy, Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $637.87 | 2019-2025 | Trintellix |
| Almatica Pharma LLC | $524.51 | 2023-2025 | Loreev Xr |
| Tris Pharma INC | $493.37 | 2019-2025 | Dyanavel Xr |
| Corium, LLC | $458.70 | 2022-2025 | Azstarys |
| Vanda Pharmaceuticals INC. | $352.44 | 2021-2025 | Fanapt, Hetlioz |
| Bausch Health US, LLC | $327.29 | 2022-2025 | Aplenzin |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $262.11 | 2021-2025 | Qelbree, Qelbree |
| Alkermes, INC. | $248.79 | 2022-2025 | Aristada, Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $168.66 | 2024-2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $94.38 | 2023 | Quviviq |
| Neos Therapeutics, LP | $89.05 | 2024-2025 | Adzenys Xr-Odt, Exxua |
| Noven Therapeutics, LLC | $63.97 | 2024 | Xelstrym, Secuado |
| Ironshore Pharmaceuticals INC. | $46.41 | 2019-2023 | Jornay Pm |
| Shire North American Group INC | $43.76 | 2019 | |
| Collegium Pharmaceutical, INC. | $42.97 | 2025 | Jornay Pm |
| Adlon Therapeutics L.P. | $32.08 | 2019-2020 | |
| Eisai INC. | $11.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maribel Aguilera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.